来源：新浪基金∞工作室 数据显示，1月6日，港股通创新药ETF工银(159217)遭净赎回926.56万元，位居当日跨境ETF净流出排名 15/207。最新规模50.48亿元，前一日规模50.17亿元，当日资金净流出额占前一日规模的比例为0.18%。 近5日，港股通创新药ETF工银(159217)遭净赎回9427.57万元，位居跨境ETF净流出排名第16/207。近10 日，港股通创新药ETF工银(159217)遭净赎回1.22亿元，位居跨境ETF净流出排名第15/207。近20日，港 股通创新药ETF工银(159217)遭净赎回1.16亿元，位居跨境ETF净流出排名第10/207。 港股通创新药ETF工银（159217）成立于2025年3月26日，基金全称为工银瑞信国证港股通创新药交易 型开放式指数证券投资基金，基金简称为港股通创新药ETF工银。该基金管理费率每年0.40%，托管费 率每年0.07%。港股通创新药ETF工银（159217）跟踪标的指数为港股通创新药（987018）。 规模方面，截止1月6日，港股通创新药ETF工银（159217）最新份额为37.51亿份，最新规模为50.48亿 元。回顾202 ...

Core Insights - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a net redemption of 2.867 million yuan on December 1, ranking 15th out of 198 in cross-border ETF net outflows [1] - As of December 1, the fund's latest size is 5.56 billion yuan, down from 5.59 billion yuan the previous day, with a net outflow accounting for 0.05% of the previous day's size [1] - Over the past 5 days, the fund faced a net redemption of 4.3125 million yuan, ranking 53rd out of 198 in cross-border ETF net outflows [1] - In the last 10 days, the fund saw a net subscription of 129 million yuan, ranking 34th out of 198 in cross-border ETF net inflows [1] - Over the past 20 days, the fund had a net subscription of 251 million yuan, ranking 36th out of 198 in cross-border ETF net inflows [1] Fund Details - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07% [1] - The fund tracks the Hong Kong Stock Connect Innovative Drug Index (987018) [1] - As of December 1, the fund's total shares are 3.865 billion, with a total size of 5.56 billion yuan [1] Liquidity and Performance - As of December 1, the fund's cumulative trading amount over the last 20 trading days is 13.981 billion yuan, with an average daily trading amount of 699 million yuan [2] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 43.85% and 63.95% respectively since their management began [2] Top Holdings - The fund's top holdings include: - 百济神州 (10.84%, 314.54 million shares, 589 million yuan) - 康方生物 (10.77%, 454.20 million shares, 586 million yuan) - 信达生物 (10.43%, 644.10 million shares, 567 million yuan) - 中国生物制药 (9.82%, 7184.50 million shares, 534 million yuan) - 石药集团 (7.72%, 4908.40 million shares, 420 million yuan) - 三生制药 (7.41%, 1469.60 million shares, 403 million yuan) - 翰森制药 (5.50%, 908.20 million shares, 299 million yuan) - 科伦博泰生物-B (3.55%, 41.14 million shares, 193 million yuan) - 再鼎医药 (2.79%, 621.62 million shares, 151 million yuan) [2] Comparative Analysis - Other ETFs tracking the Hong Kong Stock Connect Innovative Drug Index include: - 汇添富国证港股通创新药ETF (159570) with a size of 23.978 billion yuan and a recent average daily trading amount of 2.652 billion yuan [2] - 港股创新药ETF (159567) with a size of 8.460 billion yuan and a recent average daily trading amount of 1.457 billion yuan [2] - 南方国证港股通创新药ETF (159297) with a size of 1.459 billion yuan and a recent average daily trading amount of 0.115 billion yuan [2] - 鹏华国证港股通创新药ETF (159286) with a size of 0.607 billion yuan and a recent average daily trading amount of 0.088 billion yuan [2]

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 43.85%，近一个月回报为2.20%。 来源：新浪基金∞工作室 12月1日，港股通创新药ETF工银（159217）跌0.62%，成交额4.64亿元。当日份额减少200.00万份，最 新份额为38.65亿份，近20个交易日份额增加1.73亿份。最新资产净值计算值为55.60亿元。 ...

来源：新浪基金∞工作室 11月20日，港股通创新药ETF工银（159217）涨0.21%，成交额7.22亿元。当日份额增加8500.00万份， 最新份额为38.65亿份，近20个交易日份额增加4.45亿份。最新资产净值计算值为55.43亿元。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 43.42%，近一个月回报为-1.23%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 48.64%，近一个月回报为4.74%。 11月14日，港股通创新药ETF工银（159217）跌1.00%，成交额11.26亿元。当日份额增加4100.00万份， 最新份额为37.64亿份，近20个交易日份额增加3.41亿份。最新资产净值计算值为55.95亿元。 ...

港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 39.52%，近一个月回报为-12.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 来源：新浪基金∞工作室 11月4日，港股通创新药ETF工银（159217）跌2.75%，成交额7.89亿元。当日份额增加1900.00万份，最 新份额为37.11亿份，近20个交易日份额增加2.99亿份。最新资产净值计算值为51.78亿元。 ...

来源：新浪基金∞工作室 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 港股通创新药ETF工银（159217）业绩比较基准为经汇率调整后的国证港股通创新药指数收益率，管理 人为工银瑞信基金管理有限公司，基金经理为刘伟琳、焦文龙，成立（2025-03-26）以来回报为 58.14%，近一个月回报为-4.25%。 9月19日，港股通创新药ETF工银（159217）跌1.38%，成交额4.92亿元。当日份额增加100.00万份，最 新份额为33.68亿份，近20个交易日份额增加4800.00万份。最新资产净值计算值为53.26亿元。 ...

Group 1 - The ETF market showed mixed performance on the 7th, with the medical device ETF (159797) leading gains at 2.24% [2] - The Sci-Tech chip design ETF (588780) also saw an increase of 2.11%, along with the medical device index ETF (159898) which rose by 2.11% [2] - Conversely, the N-Hong Kong Stock Connect innovative drug ETF by Jiashi (520970) experienced the largest decline at 3.04%, followed by the Sci-Tech innovative drug ETF by Guotai (589720) which fell by 2.96%, and the Hong Kong Stock Connect innovative drug ETF by ICBC (159217) which dropped by 2.93% [2]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a decline of 0.26% on August 4, with a trading volume of 845 million yuan [1] - The fund's shares decreased by 19 million to a total of 3.504 billion shares, with a reduction of 291 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 5.355 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wenlong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 52.81%, with a one-month return of 16.12% [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has achieved a 68.7% increase over the past year, ranking first among similar indices [1][3] - The ETF has seen significant trading activity, with a recent trading volume of 572 million yuan and a turnover rate of 14.22%, indicating high liquidity [1] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase significant advancements in cancer treatment, with a focus on innovative therapies [1][2] Group 2 - Chinese innovative drug companies are gaining international recognition, with a record number of 71 original research results presented at the ASCO meeting, indicating a growing global presence [2] - The ASCO meeting is anticipated to further update clinical data and reports, potentially increasing interest in innovative drugs [2] - The positive cycle of innovation, commercialization, and reinvestment in research is being validated, with expectations that "License out + equity cooperation" will become mainstream for international expansion [2] Group 3 - The National Index for Hong Kong Stock Connect Innovative Drugs has a low price-to-earnings ratio of 27.25, indicating a favorable valuation position [3] - The index's constituent stocks are heavily concentrated in the biopharmaceutical and chemical drug sectors, which together account for 94.2% of the index [3] - The ETF has the lowest fee rate among similar products, which reduces holding costs and enhances liquidity through T+0 trading [3]